Ondansetron Injection is an antiemetic and is indicated for the prevention of nausea and vomiting associated with cancer chemotherapy and postoperative conditions.
Arthur Przybyl, president and CEO of Akorn, said: “We are excited to announce these two ANDA product approvals for Ondansetron Injection.”